scholarly journals Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs

2021 ◽  
Vol 20 (5) ◽  
pp. 446-450
Author(s):  
Leyla S. Namazova-Baranova ◽  
Andrey L. Bakulev ◽  
Nikolay N. Murachkin ◽  
Lyudmila N. Nam ◽  
Roman A. Ivanov

The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab. The review of international randomized trials on clinical efficacy and safety of genetically engineered biologic drug secukinumab in children and adolescents with psoriasis is presented. During treatment periods of 12 to 52 weeks, secukinumab has shown high therapeutic efficacy for psoriasis severity and skin lesion areas and has improved quality of life of children and adolescents according to dynamic assessments of PASI, IGA 0/1 mod 2011 indices, CDLQI questionnaire. The safety profile of secukinumab in children is estimated as favorable and comparable to using it in adults.

ORL ro ◽  
2016 ◽  
Vol 4 (1) ◽  
pp. 40-42
Author(s):  
Alexandra Boloș ◽  
Sebastian Cozma ◽  
Andreea Silvana Szalontay

Tinnitus is a common otologic symptom and probably the most troublesome. Tinnitus causes a number of physical and psychological consequences, that interfere with the quality of life of the patient. Many authors believe that the presence of tinnitus in children is a matter of lesser importance than in adults because it is met less frequently and would be a fleeting symptom, inoffensive for them (Graham, 1981). In addition, the prevalence of tinnitus during adolescence and even in young adults is increasing, possibly as a consequence of the increased ambient noise (Bulbul SF, Shargorodsky J). Various therapeutic approaches have generated different results, which led us to consider the role of psychological factors, hence the need to underline the particularities of this symptom in childhood.  


Autism ◽  
2013 ◽  
Vol 18 (5) ◽  
pp. 502-510 ◽  
Author(s):  
Rebecca L McStay ◽  
Cheryl Dissanayake ◽  
Anke Scheeren ◽  
Hans M Koot ◽  
Sander Begeer

2004 ◽  
Vol 22 (9) ◽  
pp. 1743-1752 ◽  
Author(s):  
Ezra E.W. Cohen ◽  
Mark W. Lingen ◽  
Everett E. Vokes

Treatment of squamous cell carcinoma of the head and neck (SCCHN) has evolved greatly in the last two decades, owing to the integration of chemotherapy, advances in radiotherapeutic techniques, and organ-preserving surgery. Several randomized trials have established new standards of care that should be adopted. Current efforts are building on these earlier trials in order to improve survival and quality of life. Coincident with this, investigators are developing molecularly targeted approaches that hold promise for the future. This review will focus on current therapy for locally advanced, recurrent, and metastatic SCCHN and discuss controversies and directions for future research.


2007 ◽  
Author(s):  
Jeffrey I. Gold ◽  
Trina Haselrig ◽  
D. Colette Nicolaou ◽  
Katharine A. Belmont

Sign in / Sign up

Export Citation Format

Share Document